Literature DB >> 18052821

Tubeless percutaneous nephrolithotomy: 5 years of experience in 201 patients.

Hossein Karami1, Mohammad Jabbari, Amir Haji Mohammad Mehdi Arbab.   

Abstract

BACKGROUND AND
PURPOSE: Our aim was to evaluate the safety, effectiveness, and feasibility of tubeless percutaneous nephrolithotomy (PCNL). PATIENTS AND METHODS: From June 2000 to September 2005, 201 patients with renal stones >2 cm underwent tubeless PCNL by a single surgeon. We report details of the outcomes.
RESULTS: The complete stone clearance rate was 91.04% (183 patients). After surgery, 18 patients (8.96%) had stones (mean size = 7 mm) detected on a plain abdominal radiograph or ultrasonographic examination and were referred for shockwave lithotripsy. The mean stone size was 30 mm (range 20-40 mm). The mean operative time was 35 minutes (range 30-60 min), and the mean hospital stay was 3.5 days (range 2-5 days). Postoperative ultrasonography did not reveal considerable fluid collection. There were no visceral injuries. Twenty-two (10.9%) patients received a transfusion, and 16 (7.9%) patients had urinary tract infection.
CONCLUSION: In our experience, tubeless PCNL is safe, effective, and feasible without any discomfort for patients.

Entities:  

Mesh:

Year:  2007        PMID: 18052821     DOI: 10.1089/end.2007.0406

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  3 in total

1.  Tubeless percutaneous nephrolithotomy.

Authors:  Madhu Sudan Agrawal; Mayank Agrawal
Journal:  Indian J Urol       Date:  2010 Jan-Mar

2.  'Nephrostomy-free' percutaneous nephrolithotomy: experience in a UK district general hospital.

Authors:  D R Yates; R K Safdar; P A Spencer; B T Parys
Journal:  Ann R Coll Surg Engl       Date:  2009-08-14       Impact factor: 1.891

3.  Percutaneous nephrolithotomy: Large tube, small tube, tubeless, or totally tubeless?

Authors:  Madhu S Agrawal; Mayank Agarwal
Journal:  Indian J Urol       Date:  2013-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.